ITOS - iTeos presents early data for lead asset EOS-448 in solid tumors

An abstract posted ahead of AACR annual meeting 2021 demonstrates the initial data from an early-stage study for solid tumors evaluating the safety and tolerability of EOS-448, one of the lead assets of iTeos Therapeutics (ITOS).EOS-448 is an anti-TIGIT human immunoglobulin G1 that has the potential to inhibit TIGIT, a cell surface receptor expressed on various immune cells in the microenvironment of most tumors.The preliminary analysis included the data as of December 15 from Phase I dose-escalation part of the multicenter, Phase I/IIa clinical trial (NCT04335253) which was designed to evaluate EOS-448 as monotherapy in patients with advanced solid tumors.22 adult patients who had at least one prior anti-cancer therapy were evaluated in cohorts of at least three participants. Highlights of the abstract are as follows.There were 54 treatment-related adverse events. 16 were immune-related. The most common adverse events included Grade 1-2 rash and pruritus. However, there were no drug-related Grade

For further details see:

iTeos presents early data for lead asset EOS-448 in solid tumors